Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 2
1995 1
1996 2
1997 1
1998 2
1999 2
2000 2
2001 8
2002 2
2003 4
2004 1
2005 1
2006 11
2007 1
2009 1
2018 1
2020 3
2021 3
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

48 results
Results by year
Filters applied: . Clear all
Page 1
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.
Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG, Jeffery DA, Spoerke JM, Honigberg LA, Young PR, Dalrymple SA, Palmer JT. Pan Z, et al. Among authors: sprengeler pa. ChemMedChem. 2007 Jan;2(1):58-61. doi: 10.1002/cmdc.200600221. ChemMedChem. 2007. PMID: 17154430 No abstract available.
Perspectives on factor Xa inhibition.
Rai R, Sprengeler PA, Elrod KC, Young WB. Rai R, et al. Among authors: sprengeler pa. Curr Med Chem. 2001 Feb;8(2):101-19. doi: 10.2174/0929867013373822. Curr Med Chem. 2001. PMID: 11172669 Review.
Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A.
Thompson PA, Eam B, Young NP, Fish S, Chen J, Barrera M, Howard H, Sung E, Parra A, Staunton J, Chiang GG, Gerson-Gurwitz A, Wegerski CJ, Nevarez A, Clarine J, Sperry S, Xiang A, Nilewski C, Packard GK, Michels T, Tran C, Sprengeler PA, Ernst JT, Reich SH, Webster KR. Thompson PA, et al. Among authors: sprengeler pa. Mol Cancer Ther. 2021 Jan;20(1):26-36. doi: 10.1158/1535-7163.MCT-19-0973. Epub 2020 Oct 9. Mol Cancer Ther. 2021. PMID: 33037136 Free article.
Potent 4-amino-5-azaindole factor VIIa inhibitors.
Hu H, Kolesnikov A, Riggs JR, Wesson KE, Stephens R, Leahy EM, Shrader WD, Sprengeler PA, Green MJ, Sanford E, Nguyen M, Gjerstad E, Cabuslay R, Young WB. Hu H, et al. Among authors: sprengeler pa. Bioorg Med Chem Lett. 2006 Sep 1;16(17):4567-70. doi: 10.1016/j.bmcl.2006.06.016. Epub 2006 Jun 21. Bioorg Med Chem Lett. 2006. PMID: 16793264
Novel 5-azaindole factor VIIa inhibitors.
Riggs JR, Hu H, Kolesnikov A, Leahy EM, Wesson KE, Shrader WD, Vijaykumar D, Wahl TA, Tong Z, Sprengeler PA, Green MJ, Yu C, Katz BA, Sanford E, Nguyen M, Cabuslay R, Young WB. Riggs JR, et al. Among authors: sprengeler pa. Bioorg Med Chem Lett. 2006 Jun 15;16(12):3197-200. doi: 10.1016/j.bmcl.2006.03.049. Epub 2006 Apr 18. Bioorg Med Chem Lett. 2006. PMID: 16621549
Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase.
Ernst JT, Thompson PA, Nilewski C, Sprengeler PA, Sperry S, Packard G, Michels T, Xiang A, Tran C, Wegerski CJ, Eam B, Young NP, Fish S, Chen J, Howard H, Staunton J, Molter J, Clarine J, Nevarez A, Chiang GG, Appleman JR, Webster KR, Reich SH. Ernst JT, et al. Among authors: sprengeler pa. J Med Chem. 2020 Jun 11;63(11):5879-5955. doi: 10.1021/acs.jmedchem.0c00182. Epub 2020 May 29. J Med Chem. 2020. PMID: 32470302
Structure-guided design of peptide-based tryptase inhibitors.
McGrath ME, Sprengeler PA, Hirschbein B, Somoza JR, Lehoux I, Janc JW, Gjerstad E, Graupe M, Estiarte A, Venkataramani C, Liu Y, Yee R, Ho JD, Green MJ, Lee CS, Liu L, Tai V, Spencer J, Sperandio D, Katz BA. McGrath ME, et al. Among authors: sprengeler pa. Biochemistry. 2006 May 16;45(19):5964-73. doi: 10.1021/bi060173m. Biochemistry. 2006. PMID: 16681368
48 results